IQVIA Holdings Inc. (NYSE:IQV) Short Interest Up 11.0% in December

IQVIA Holdings Inc. (NYSE:IQV) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 3,120,000 shares, an increase of 11.0% from the December 15th total of 2,810,000 shares. Based on an average daily volume of 1,530,000 shares, the days-to-cover ratio is currently 2.0 days. Currently, 1.7% of the company’s shares are sold short.

IQVIA Stock Performance

Shares of NYSE:IQV traded down $0.41 during trading on Monday, hitting $197.25. 1,253,280 shares of the company traded hands, compared to its average volume of 1,057,891. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The business’s fifty day moving average is $200.09 and its 200-day moving average is $221.39. The stock has a market capitalization of $35.80 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 2.09 and a beta of 1.48. IQVIA has a one year low of $187.62 and a one year high of $261.73.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Capital Performance Advisors LLP acquired a new position in shares of IQVIA during the third quarter valued at $27,000. Park Place Capital Corp bought a new stake in IQVIA in the 3rd quarter valued at about $28,000. Itau Unibanco Holding S.A. acquired a new position in IQVIA during the 2nd quarter valued at about $29,000. Avior Wealth Management LLC grew its position in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the last quarter. Finally, Assetmark Inc. increased its stake in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Bank of America decreased their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Stephens assumed coverage on IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective on the stock. Evercore ISI decreased their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Truist Financial dropped their target price on IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $255.82.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.